Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 agents demonstrate promising therapeutic outcomes in treating type 2